Skip to main content

Hambleton Julie's Form 4 filing

IGM Biosciences, Inc. (IGMS) · filed Jul 29, 2024

Accession no.
0001415889-24-020266
Filed
Jul 29, 2024
Trade date
Jul 25, 2024
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $211.8K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Hambleton JulieCIK 0001578771Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 25, 2024Common StockMOption exerciseAcquired+15,132$1.39+$21,033.4817,132Direct
Jul 25, 2024Common StockSSaleDisposed−15,132$14.00−$211,8482,000Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jul 25, 2024Common StockMOption exerciseDisposed−15,132$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)